Testing a donor immune cell therapy for cancer that has spread to the brain
Original title: The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test, and it has not shown yet whether the therapy helps.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new immune cell treatment given right into the brain.
Who this trial is for. This trial is for people whose advanced cancer has spread to the brain. Their brain tumors must test positive for a marker called B7-H3. It tests a donor cell therapy called MT027, placed into the fluid spaces of the brain.
Where it stands. The trial has not reported results. It starts with a small safety stage of 3 to 6 people. If that stage looks safe enough, 34 more people join. The team is checking how safe the therapy is and how it acts on tumors in the brain. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Nothing here says this therapy works. If this sounds like your situation, you could ask your care team about it. They know your case and can say whether a study like this is worth looking into.
What it doesn't mean: This does not mean the treatment is proven. A trial is a test, not care your own doctor can give you. Being in a trial is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, October 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.